Prolonged in vitro exposure to increasing concentrations of lenalidomide resulted in IMiD-resistant myeloma cells with reduced CRBN expression caused by deletion of one copy of CRBN [42]. This evidence concerns the gene CRBN and plasma cell myeloma.